Disease · MONDO_0000565
infective endocarditis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. infective endocarditis. Diseases, record MONDO_0000565. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0000565
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs19
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DAPTOMYCIN | CHEMBL387675 | Small molecule | Approval | PMDA | 4 | 3 | 3 | Drugs and targets |
| VANCOMYCIN | CHEMBL262777 | Small molecule | Approval | FDA | 3 | 2 | 2 | Drugs and targets |
| CEFTOBIPROLE MEDOCARIL SODIUM | CHEMBL4297101 | Small molecule | Approval | FDA | 2 | 1 | 1 | Drugs and targets |
| AMOXICILLIN | CHEMBL1082 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CEFAZOLIN | CHEMBL1435 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EXEBACASE | CHEMBL4297925 | Enzyme | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LEVOFLOXACIN | CHEMBL5315124 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PENICILLIN G POTASSIUM | CHEMBL1223 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RIFAMPIN | CHEMBL374478 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TELAVANCIN | CHEMBL507870 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 19
See all 19 drugsTargets12
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PTGS1 | Cyclooxygenase | 1 | Cyclooxygenase inhibitor | Phase 2 | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 1 | Cyclooxygenase inhibitor | Phase 2 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| SCN10A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6336 | Drugs and targets |
| SCN11A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/11280 | Drugs and targets |
| SCN1A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6323 | Drugs and targets |
| SCN2A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6326 | Drugs and targets |
| SCN3A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6328 | Drugs and targets |
| SCN4A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6329 | Drugs and targets |
| SCN5A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6331 | Drugs and targets |
| SCN7A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 2 | https://conductscience.org/library/genes/6332 | Drugs and targets |
1 to 10 of 12
See all 12 targetsTrials11
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03138733 | Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia | Phase 3 | 390 | 2023-05-06 | Staphylococcus Aureus Bacteremia | CEFTOBIPROLE MEDOCARIL SODIUM, DAPTOMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT04160468 | Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase | Phase 3 | 259 | 2023-10-18 | Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis | EXEBACASE | Its record names the disease | ClinicalTrials.gov |
| NCT04775953 | DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia | Phase 2 | 200 | 2024-10-22 | Staphylococcal Bacteraemia | DALBAVANCIN | Its record names the disease | ClinicalTrials.gov |
| NCT02208063 | A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial | Phase 3 | 121 | 2020-02-17 | Bacteremia | CEFAZOLIN, DAPTOMYCIN, PENICILLIN G POTASSIUM, TELAVANCIN, VANCOMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT03148756 | Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis | Phase 2 | 2 | 2018-09-10 | Endocarditis, Bacteremia | DALBAVANCIN | Its record names the disease | ClinicalTrials.gov |
| NCT02701595 | Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus | Phase 3 | 324 | Infective Endocarditis | AMOXICILLIN | Its record names the disease | ClinicalTrials.gov | |
| NCT02701608 | Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus | Phase 3 | 162 | Infective Endocarditis | LEVOFLOXACIN, RIFAMPIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01571791 | Perioperative Ketorolac-lidocaine in the Patients With Valvular Heart Diseases During Cesarean Delivery | Phase 2 | 90 | Valve Heart Disease, Elective Cesarean Delivery | KETOROLAC, LIDOCAINE | Its record names the disease | ClinicalTrials.gov | |
| NCT03688659 | Vancomycin, Gentamycin in Infective Endocarditis | Not applicable | 30 | Infective Endocarditis | GENTAMICIN, VANCOMYCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT07550595 | Oritavancin for Treatment of Serious Cardiac Infections | Phase 2 | 20 | Infective Endocarditis, Cardiac Device Infection, Gram-positive Bacterial Infections | ORITAVANCIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 11
See all 11 trialsComparisons in its trials18
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ceftobiprole vs Daptomycin: deaths from any cause | 17 of 191 | 18 of 198 | 389 | NCT03138733 | Trial comparisons |
| Ceftobiprole vs Daptomycin: serious adverse events | 36 of 191 | 45 of 198 | 389 | NCT03138733 | Trial comparisons |
| Ceftobiprole vs Daptomycin: Number of Patients With Microbiological Eradication at the PTE Visit | 155 of 189 | 153 of 198 | 387 | NCT03138733 | Trial comparisons |
| Exebacase + SoCA vs SoCA Alone: Treatment-emergent Adverse Events (TEAEs) Through Day 60 | 142 of 165 | 72 of 85 | 250 | NCT04160468 | Trial comparisons |
| Exebacase + SoCA vs SoCA Alone: deaths from any cause | 27 of 165 | 14 of 85 | 250 | NCT04160468 | Trial comparisons |
| Exebacase + SoCA vs SoCA Alone: serious adverse events | 71 of 165 | 34 of 85 | 250 | NCT04160468 | Trial comparisons |
| Dalbavancin vs Standard of Care: Frequency of All-Cause Mortality (A Component of DOOR) | 4 of 100 | 4 of 100 | 200 | NCT04775953 | Trial comparisons |
| Dalbavancin vs Standard of Care: Frequency of AEs Leading to Study Drug Discontinuation | 3 of 100 | 12 of 100 | 200 | NCT04775953 | Trial comparisons |
| Dalbavancin vs Standard of Care: Frequency of Clinical Efficacy | 73 of 100 | 72 of 100 | 200 | NCT04775953 | Trial comparisons |
| Dalbavancin vs Standard of Care: Frequency of SAEs (A Component of DOOR) | 40 of 100 | 34 of 100 | 200 | NCT04775953 | Trial comparisons |
1 to 10 of 18
See all 18 comparisons in its trialsPapers from its trials9
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0000565
GET https://conductscience.org/api/diseases/v1/MONDO_0000565/drugs